PRF Technologies Ltd. Ordinary Shares
PRFXPainReform Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for chronic pain conditions. The company utilizes novel proprietary drug delivery technologies to enhance the efficacy and safety of pain management therapies. PainReform's pipeline emphasizes non-opioid solutions aimed at providing long-lasting relief for patients with unmet needs in pain treatment.
Company News
PRF Technologies announced FDA clearance of its Investigational New Drug (IND) application for OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract surgery pain and inflammation. The company plans to initiate a Phase II clinical trial in the United States with patient enrollment expected in the second half...
PRF Technologies (NASDAQ: PRFX) shares tumbled on Tuesday as the broader market traded lower and investors digested the company's year-end business update. The stock, down 76.25% over the past 12 months, continues to face headwinds despite the company's strategic repositioning into a diversified platform spanning specialty pharmaceuticals and AI-...
PainReform's DeepSolar business unit launched Smart TDD, an advanced solar Technical Due Diligence service designed to provide faster and more comprehensive assessments of solar asset performance. The service targets the $60+ billion annual solar asset M&A market by offering complete data coverage, AI-driven diagnostics, and rapid turnaround to s...
BladeRanger (TASE: BLRN), a drone-based inspection and AI analytics provider for green energy infrastructure, will showcase its Solar Drone and DeepSolar platforms at Abu Dhabi Sustainability Week. The company is expanding its regional presence in the UAE, where $600 billion is being invested in hyperscale data centers and renewable energy system...
PainReform Ltd. has acquired a majority equity stake in LayerBio, a biotechnology company developing a breakthrough non-opiate, non-steroidal drug delivery system for postoperative pain management in cataract surgery, targeting the $9B global market.
